Julie Rubinstein, who serves as president and chief operating officer of Adaptive Biotechnologies Corp (NASDAQ: ADPT), disposed of 68,261 shares of the company’s common stock across transactions executed from April 6 to April 8, 2026. The sales were carried out under a pre-arranged 10b5-1 trading plan and occurred at prices ranging from $13.56 to $15.48, producing total gross proceeds of about $990,503.
Concurrently with the disposition, Rubinstein exercised stock options to acquire a total of 41,325 shares of Adaptive Biotechnologies common stock. Those option exercises were executed at strike prices of $7.27 and $12.14 and represent a combined value of $465,322 based on the exercise prices.
After completing these transactions, Rubinstein’s direct ownership stands at 434,188 shares of Adaptive Biotechnologies common stock.
The share sales occurred against a backdrop of sizable recent gains for the company’s stock. Over the past year the shares have returned 94%, although the share price has exhibited notable volatility, reflected in a beta of 2.3. Separately, analysis indicates the company is valued at approximately $2.27 billion and that the stock currently trades above its assessed fair value, a consideration some investors may wish to examine further.
Earnings and analyst reactions
Adaptive Biotechnologies reported fourth-quarter 2025 results that outpaced analyst expectations on both the earnings and top-line fronts. The company posted an adjusted loss per share of -$0.09, compared with an anticipated -$0.18, representing a 50% positive surprise relative to consensus estimates. Revenue for the quarter reached $71.7 million, topping the forecasted $59.33 million by 20.85%.
Following the earnings release, several research firms updated their views. BTIG raised its price target to $22 from $21 and maintained a Buy rating, citing strong growth within Adaptive’s core Minimal Residual Disease (MRD) business. That segment grew 54% year-over-year in Q4 2025 and contributed to a 46% increase in MRD revenue for the full year. TD Cowen lifted its price target to $21 from $20, and Piper Sandler reiterated an Overweight rating, highlighting the company’s position in the MRD space.
What the transactions and results mean
- Rubinstein’s sales were executed under a pre-set 10b5-1 trading arrangement and totaled 68,261 shares sold for roughly $990,503 between April 6 and April 8, 2026.
- She exercised options for 41,325 shares at $7.27 and $12.14, with the exercises valued at $465,322 based on those option prices.
- Post-transactions, Rubinstein holds 434,188 shares directly.
The company’s latest quarterly performance and subsequent analyst updates underscore robust growth in Adaptive’s MRD business, while the insider transactions provide a contemporaneous view of executive-level activity in the shares.